In a mouse tumor model, the inhibition of CDK5 expression or the combination of CDK5 inhibition with anti-PD-L1 therapy can significantly inhibit tumor growth and lead to increased levels of CD3+, CD4+, and CD8+ T cells in the spleen and decreased PD-1 expression in the CD4+ T cells30. The gene discussed is CD4; the disease is neoplasm.